Paget's bone disease, also known as osteitis deformans, is characterized by a significant increase in bone resorption and turnover in localized parts of the skeleton causing enlargement and thickening of the bone that is disordered and architecturally unstable.
The prevalence increases with age, with men and women affected equally.
Genetic factors and/or viral infection may play a role in the etiology.
May affect one bone (monostotic) or several bones (polyostotic).
By decreasing frequency, involved bones may include pelvic bone and sacrum, spine, skull and femur, tibia, humeri and clavicles.

Surgical Intervention

  • Eg joint replacement, osteotomy, fracture repair
  • Surgical patients should be pretreated w/ bisphosphonates to prevent serious bleeding during surgery due to hypervascularity, a symptom of active Paget’s bone disease
    • No clinical trials yet on the recommended timing of such treatment
  • Recommended for:
    • Pagetic fracture repair
    • Knee realignment to decrease mechanical pain, esp in cases where pharmacotherapy is ineffective
    • Hip/knee replacement esp in cases where antiresorptive therapy or osteoarthritis (OA) treatment is ineffective
    • Relief of compression due to pagetic vertebrae on the spinal cord or nerve roots
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Editor's Recommendations
Most Read Articles
13 Mar 2018
In obese patients with type 2 diabetes mellitus (T2DM), higher plasma levels of leptin appear to be associated with better sleep quality, a recent study has shown.
Roshini Claire Anthony, 4 days ago

Individuals with type 2 diabetes (T2D) who initiate therapy with sodium glucose cotransporter-2 (SGLT-2) inhibitors have lower risks of all-cause death and cardiovascular (CV) outcomes, specifically myocardial infarction (MI) and stroke, compared with those who initiate other glucose-lowering therapies, according to results from the CVD-REAL* 2 study.

22 Jun 2017
Circulating glucagon-like peptide 1 (GLP-1) levels increase with chronic and acute inflammatory processes like sepsis and chronic kidney disease, a recent study has found.
01 Jun 2015
New drug applications approved by US FDA as of 15 – 31 May 2015 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.